Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P G Gill

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Breast Cancer Research and Treatment|December 1, 1991
Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGFP G Gill, W D Tilley, N J De Young, et al.
Biochemical and Biophysical Research Communications|June 15, 1993
Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cellsP C Owens, P G Gill, N J De Young, et al.
The Medical Journal of Australia|January 1, 2000
Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancerJ Kollias, P G Gill, B E Chatterton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1989
Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerationsP A Reece, I Stafford, R L Abbott, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanomaA Coates, D Thomson, G R McLeod, et al.
The Medical Journal of Australia|January 4, 1988
Preliminary experience with a combined-modality approach to the management of oesophageal cancerJ W Denham, P G Gill, G G Jamieson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials GroupM J Byrne, V Gebski, J Forbes, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 1995
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter studyB H Burmeister, J W Denham, M O'Brien, et al.
Bone Marrow Transplantation|December 1, 1992
Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancerK B Pittman, L B To, J L Bayly, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1997
A combined modality approach to the management of oesophageal cancerB M Smithers, P Devitt, G G Jamieson, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Breast Cancer Research and Treatment|December 1, 1991
Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGFP G Gill, W D Tilley, N J De Young, et al.
Biochemical and Biophysical Research Communications|June 15, 1993
Estrogen and progesterone regulate secretion of insulin-like growth factor binding proteins by human breast cancer cellsP C Owens, P G Gill, N J De Young, et al.
The Medical Journal of Australia|January 1, 2000
Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancerJ Kollias, P G Gill, B E Chatterton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1989
Two- versus 24-hour infusion of cisplatin: pharmacokinetic considerationsP A Reece, I Stafford, R L Abbott, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanomaA Coates, D Thomson, G R McLeod, et al.
The Medical Journal of Australia|January 4, 1988
Preliminary experience with a combined-modality approach to the management of oesophageal cancerJ W Denham, P G Gill, G G Jamieson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 1997
Medroxyprogesterone acetate addition or substitution for tamoxifen in advanced tamoxifen-resistant breast cancer: a phase III randomized trial. Australian-New Zealand Breast Cancer Trials GroupM J Byrne, V Gebski, J Forbes, et al.
International Journal of Radiation Oncology, Biology, Physics|July 15, 1995
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter studyB H Burmeister, J W Denham, M O'Brien, et al.
Bone Marrow Transplantation|December 1, 1992
Non-haematological toxicity limiting the application of sequential high dose chemotherapy in patients with advanced breast cancerK B Pittman, L B To, J L Bayly, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|June 1, 1997
A combined modality approach to the management of oesophageal cancerB M Smithers, P Devitt, G G Jamieson, et al.
Pageof 9